ALB and hepatocellular carcinoma: Another study conducted by Campani et al. [146] showed that a high score of the pre-treatment serum ALB–BIL grade combined with post-treatment serum AFP level change was independently correlated with worse OS and PFS in HCC patients receiving molecular targeted therapy with atezolizumab and bevacizumab.